

From: [REDACTED]
To: [Bell, Simon](#); [Channing, Darrell](#)
Cc: [Exemptions](#); [REDACTED]
Subject: Medicines Australia – ACCC Authorisation AA1000486 – fortnightly report 6 March 2021 to 19 March 2021
Date: Friday, 19 March 2021 1:22:15 PM
Attachments: [image72c55b.PNG](#)
[image5f8964.PNG](#)
[imageff4892.PNG](#)
[imagef90b8d.PNG](#)
[imaged53614.GIF](#)

Dear Simon/Darrell,

In relation to the ACCC Authorisation **AA1000486** (24 September 2020) and, specifically, in accordance with the Conditions of that Authorisation at paragraph 5.12, Medicines Australia provides the following fortnightly report on activities related to the Proposed Conduct.

In the period of 6 March 2021 to 19 March 2021, no meetings or discussions of the Medicines Australia/Generic and Biosimilar Medicines Association Working Group occurred and no decisions were made that fall under the Proposed Conduct.

Medicines Australia's next fortnightly update will cover the period of 20 March 2021 to 2 April 2021. Additional updates will be provided to the ACCC as required and in accordance with Medicines Australia's obligations under the authorisation.

We also consent to this email being published on the public register, with the appropriate privacy redactions.

This response was drafted in consultation with [REDACTED], CEO of Generic and Biosimilar Medicines Association.

Yours sincerely,

[REDACTED]

Manager, Industry and Regulatory Policy
Medicines Australia

17 Denison Street

Deakin ACT 2600

Australia

Main Office: [+61 2 6147 6500](tel:+61261476500)

Mobile: [REDACTED]

Email: [REDACTED]

Web: www.medicinesaustralia.com.au



[Mdicines Australia Members Area](#)



Please consider the environment before printing this email message